Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Srt-2104. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 known ✓ | Q96EB6 | 13/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.50 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Srt-2104 SCHEMBL29438742 | 1.00 | SIRT1 (0.52) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL12092855 | 0.92 | SIRT1 (0.53) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL14617812 | 0.88 | CSNK1D (0.45) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL960810 | 0.85 | SIRT1 (0.46) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| Hydrochloric Acid SCHEMBL961500 | 0.84 | SIRT1 (0.46) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2571530 | 0.82 | SIRT1 (0.44) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL14886520 | 0.80 | SIRT1 (0.66) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL13979015 | 0.79 | SIRT1 (0.51) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL13251475 | 0.78 | SIRT1 (0.59) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL12342633 | 0.78 | CYP1A2 (0.47) | CSNK1DCSNK1ECYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661539-B1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | UNIV CALIFORNIA (US) | 2024-10-09 | — | — | EP | claimed |
| US-20240207421-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | claimed |
| US-20240124523-A1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-04-18 | — | — | US | claimed |
| WO-2022120177-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES, INC. (US) | 2022-06-09 | — | — | WO | claimed |
| US-11299515-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-12 | — | — | US | claimed |
| EP-4743083-A1 | METHODS OF TREATING FIBROTIC LIVER DISEASES OR CONDITIONS WITH INDEGLITAZAR | Pleiogenix Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260130872-A1 | Substituted Bicyclic Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026088071-A1 | SUBSTITUTED FUSED HETEROARYL LACTAM COMPOUNDS | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260092054-A1 | FUSED RING COMPOUND AND PHARMACEUTICAL CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20110015192-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015192-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015192-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100330114-A1 | Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-30 | — | — | US | disclosed |
| US-7829556-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829556-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090012080-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012080-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130872-A1 | Substituted Bicyclic Compounds, Compositions and Methods of Use | GIPR, GLP1R, SIGMAR1 | SIRT1 3671/4885CHRM2 619/4885ADRA2A 1323/4885 |
| US-20100330114-A1 | Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response | SIRT1, SIRT2, NFATC1 | SIRT1 1/4885CHRM2 473/4885ADRA2A 2603/4885 |
| US-20260092054-A1 | FUSED RING COMPOUND AND PHARMACEUTICAL CONTAINING SAME | STAT6, HRH4, CCR6 | SIRT1 2473/4885CHRM2 361/4885ADRA2A 757/4885 |
| US-20090012080-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885CHRM2 4269/4885ADRA2A 3932/4885 |
| US-20110015192-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885CHRM2 4595/4885ADRA2A 4105/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | SIRT1 4607/4885CHRM2 1291/4885ADRA2A 1410/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | SIRT1 566/4885CHRM2 2401/4885ADRA2A 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.